ADC Payload / Warheads Market

ADC Payload / Warheads Market: Distribution by Type of Product (Commercialized ADCs and Clinical ADCs), Type of Payload (Microtubule Inhibitors, DNA Damaging Agents, Topoisomerase Inhibitors and Others), Payload / Warhead (Auristatins, Calicheamicin, Camptothecin, Duocarmycin, Maytansinoids, Pyrrolobenzodiazepines and Others) and Geography (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021-2035

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    115

  • Pages
    132

  • View Count
    11041

ADC Payload / Warheads Market Overview

The ADC payload / warheads market is estimated to be worth $267 million in 2022 and is expected to grow at compounded annual growth rate (CAGR) of 12% during the forecast period. With six approved drugs, namely POLIVY™ (2019), LUMOXITI™ (2018), BESPONSA® (2017), MYLOTARG™ (2017, reapproval), KADCYLA® (2013) and ADCETRIS® (2011), and more than 300 candidates in the pipeline (clinical / preclinical stages), antibody drug conjugates (ADCs) have emerged as a promising class of therapeutics for the treatment of various disease indications. Over time, medical researchers have been able to further develop their understanding of the intricacies of ADC design and have also improved the development process of these complex pharmacological interventions. ADCs are engineered therapeutics comprised of monoclonal antibodies attached to potent cytotoxic payloads through chemical linkers. Given the fact that ADCs are highly potent cytotoxic molecules, the manufacturing of ADCs requires elaborate technical capabilities and highly potent chemical substances. Specifically, the multi-step process of production of cytotoxic payloads, which are used in ADCs, requires a contained environment, dedicated manufacturing facilities, specialized analytical and purification techniques, and storage facilities. However, several ADC developers do not have the in-house capabilities to manufacture cytotoxic payload on a commercial scale and tend to rely on contract manufacturers. As per the estimates, 70-80% of ADC manufacturing operations are outsourced.  

Since 2000, several contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs), offering HPAPI and cytotoxic drug related services have been established to cater to the rise in demand of cytotoxic payloads in ADCs and other similar therapeutic interventions. In addition, several ADC developers have forged strategic partnerships with payload providers to advance the development of pipeline ADC candidates. Given the growing clinical pipeline of ADCs, coupled to the various technological advancements, the market for ADC payloads and warheads is anticipated to witness substantial market growth during the forecast period.

This image highlights the context of ADC Cytotoxic Payloads market report. The production of ADC payloads requires technical expertise and specialized facilities; as a result, drug developers tend to rely on contract manufacturers, which offer flexibility of production, lower risk and fasten the timeline of product launch This image provides a list of of cytotoxic ADC payloads / warheads developers. Presently, around 40 companies across the globe claim to have the required expertise and capabilities to provide payloads and warheads for ADCs This image provides review of the overall market landscape of the companies offering ADC payloads and warheads. The current market landscape is a mix of both CDMOs and developers; most of them provide microtubule inhibitors and DNA damaging agents as payloads for ADCs

Key Companies in ADC Payload / Warheads Market

Examples of key companies engaged in ADC payload / warheads market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Abzena, MabPlex, Levena Biopharma, NJ Bio, Novasep, STA Pharmaceutical (a subsidiary of WuXi AppTec) and Synaffix. This market report includes an easily searchable excel database of all the companies providing ADC payload / warheads, worldwide.

Recent Developments in ADC Payload / Warheads Market:

Several recent developments have taken place in the field of ADC payload / warheads market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In September 2023, Myricx Bio entered into licensing agreement with Biocytogen Pharmaceuticals with an aim to develop and commercialize ADCs using Biocytogen’s proprietary RenMice® platform in order to strengthen its ADC pipeline of proprietary monoclonal antibodies (mAbs) against important cancer targets.

Scope of the Report

The ADC Payload / Warheads Market: Distribution by Type of Product (Commercialized ADCs and Clinical ADCs), Type of Payload (Microtubule Inhibitors, DNA Damaging Agents, Topoisomerase Inhibitors and Others), Payload / Warhead (Auristatins, Calicheamicin, Camptothecin, Duocarmycin, Maytansinoids, Pyrrolobenzodiazepines and Others) and Geography (North America, Europe, Asia-Pacific and Rest of the World)” market report offers a comprehensive study of the current market landscape, market size, market forecast and future opportunities within the ADC payload / warheads market. The market research report features an in-depth analysis, highlighting the capabilities of developers / contract services providers engaged in ADC payload / warheads market.

In addition to other elements, the market research report includes: 

  • A review of the overall market landscape of the companies offering ADC payloads and warheads, featuring a detailed analysis based on the type of payload, type of microtubule inhibitors, DNA damaging agents and toposimerase inhibitors. In addition, it includes information on the developer’s year of establishment, and location of headquarters and company size of the players.
  • Elaborate profiles of players involved in the manufacturing of ADC payloads and warheads. Each profile features a brief overview of the company, its facility location, its financial information (if available), recent developments, and an informed future outlook.
  • An analysis of the partnerships that have been established in ADC payload / warheads market since 2016, covering instances of licensing agreements, R&D agreements, mergers / acquisitions, manufacturing and supply agreements, product development agreements, service alliance, product development and commercialization agreements, and other relevant types of deals.
  • An analysis of the investments made, including seed funding, venture capital financing, debt funding, grants, capital raised from IPOs and subsequent offerings, at various stages of development, in companies focused on the development of ADC payloads and warheads.
  • A review of the expansions that have undertaken by the players engaged in developing ADC payloads and warheads for enhancing their respective offerings. It features a detailed analysis based on a number of parameters, including year of expansion, type of expansion (capacity expansion, facility expansion and new facility), location of facility and leading players.
  • An in-depth analysis of the various patents that have been filed / granted related to ADC payloads and warheads, highlighting key trends across the parameters, such as publication year, patent type, geographical location, issuing authority, assigned CPC symbol, emerging focus areas, and leading industry players (in terms of size of intellectual property portfolio). In addition, it includes a patent benchmarking analysis and a detailed valuation analysis.
  • An informed estimate of the annual clinical / commercial demand for ADC paylaods and warheads (in kilograms), taking into account parameters such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.
  • A case study on the ADCs that are already approved and those that are under development (clinical and preclinical), providing information on their phase of development (approved, clinical and preclinical / discovery stage), therapeutic area, line of treatment, dosing regimen, target antigen, antibody isotype, type of linker, type of payload / warhead and type of payload category. In addition, it provides a list of ADC developers, along with information on their year of establishment, company size and geography. The chapter also highlights the key players (in terms of number of drugs developed) in this industry. 
This image highlights in-depth analysis of the various patents that have been filed / granted related to ADC payloads and warheads. Over time, the intellectual property related to ADC payloads / warheads has grown at a significant rate, primarily for ADCs containing auristatin, calicheamicin and maytansinoids as payloads This image represents the partnerships activities that have been established in the domain of ADC cytotoxic payloads. In the past few years, a steady increase in partnership activity has also been observed; a relatively higher proportion of deals were inked for licensing of payloads / warheads to develop ADCs This image highlights expansions that have undertaken by the players engaged in developing ADC payloads and warheads. To meet the growing demand for ADC therapeutics, several ADC payloads / warheads developers are actively investing in expanding their existing infrastructure
  • A case study on the ADC contract manufacturing market, highlighting a list of contract service providers and in-house manufacturers that are currently active in this space. The chapter includes a detailed review of the overall landscape of companies offering contract services for the manufacturing of ADCs, along with information on the type of service offered, other services offered, scale of operation (preclinical, clinical and commercial) and location of manufacturing facilities.

One of the key objectives of this market report is to provide a detailed market forecast analysis in order to estimate the existing market size and future opportunity of the ADC payload / warheads market during forecast period. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] type of payload (microtubule inhibitors, DNA damaging agents, topoisomerase inhibitors and Others) [B] payload / warhead (maytansinoids, auristatins, camptothecins, maytansinoids, pyrrolobenzodiazepines, calicheamicin, duocarmycin and Others), [C] type of product (clinical and commercial ADC) and [D] key geographies (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the anticipated industry’s growth.

The opinions and insights presented in the market report were influenced by discussions held with senior stakeholders in the industry. The market research report features detailed transcripts of interviews held with the following industry stakeholders:

  • Kevin Daley (Market Director, Novasep)
  • Floris Van Delft (Founder and Chief Scientific Officer, Synaffix)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

This image provides analysis on the investments made in companies focused on the development of ADC payloads and warheads. Given the growing popularity of ADC therapeutics, there has been a steady rise in the interest of strategic investors and venture capital firms over the last five years This image represents an informed estimate of the annual clinical / commercial demand for ADC paylaods and warheads. With the success of marketed products and anticipated approval of new ADCs, the demand for ADC payloads / warheads is expected to steadily increase The image provides a detailed market sizing of ADC cytotoxic payloads market. We anticipate the ADC payloads / warheads market to grow at an annualized rate of over 10% during the next decade; the opportunity is likely to be well-distributed across different regions worldwide

Frequently Asked Questions

Question 1: What are ADC?

Answer: ADC or antibody drug conjugates belong to a class biopharmaceuticals developed for treating cancer. Contrary to chemotherapy, ADC are targeted to kill tumor cells while sparing healthy cells.

Question 2: How big is the ADC payload / warheads market?

Answer: The ADC payload / warheads market size is estimated to be worth $267 million in 2022.

Question 3: What is the projected market growth of the ADC payload / warheads market?

Answer: The ADC payload / warheads market is expected to grow at compounded annual growth rate (CAGR) of over 12% during the forecast period 2022 - 2035.

Question 4: Who are the leading players in the ADC payload / warheads market?

Answer: Examples of key companies engaged in ADC payload / warheads market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Abzena, MabPlex, Levena Biopharma, NJ Bio, Novasep, STA Pharmaceutical (a subsidiary of WuXi AppTec) and Synaffix.

Question 5: How many companies are currently engaged in the ADC payload / warheads market?

Answer: Over 40 companies are currently engaged in the ADC payload / warheads market.

Question 6: How much funding has been raised by companies engaged in the ADC payload / warheads market?

Answer: Over USD 1 billion has been raised by companies engaged in the ADC payload / warheads market.

Question 7: Which region is the hub for companies engaged in the ADC payload / warheads market?

Answer: Europe emerged as the hub for companies engaged in the ADC payload / warheads market, with over 45% of the players established in the region.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com